oppn parties Maiden Pharma Cough Syrup Case: Did WHO Act In Haste?

News Snippets

  • Batteries, chains and screws were among 65 objects found in the stomach of a 14-year-old Hathras boy who died after these objects were removed in a complex surgery at Delhi's Safdarjung Hospital
  • India confirms that 'verification patrolling' is on at Demchok and Depsang in Ladakh after disengagement of troops
  • LeT commander and 2 other terrorists killed in Srinagar in a gunbattle with security forces. 4 security personnel injured too.
  • Man arrested in Nagpur for sending hoax emails to the PMO in order to get his book published
  • Adani Power sets a deadline of November 7 for Bangladesh to clear its dues, failing which the company will stop supplying power to the nation
  • Shubman Gill (90) and Rishabh Pant (60) ensure India get a lead in the final Test after which Ashwin and Jadeja reduce the visitors to 171 for 9 in the second innings
  • Final Test versus New Zealand: Match evenly poised as NZ are 143 ahead with 1 wicket in hand
  • PM Modi said that a historic Diwali will be celebrated in Ayodhya after 500 years with the rebuilding of the Ram Mandir there
  • Priyanka Gandhi, campaigning as the candidate in Wayanad, alleged that the BJP had neglected the constituency
  • UP Police arrested 7 people for selling firearms on WhatsApp, Instagram and Facebook
  • The Election Commission once again slammed the Congress for 'frivolous doubts' on the Haryana election process
  • Government has advised pharma companies to cut prices of cancer drugs as the customes duty has been slashed
  • Bengal tweaks PMAY scheme to make it 'better' than the Central offer
  • PM Modi slams Delhi and Bengal for not rolling out Ayushman Bharat in their states. TMC rebuts the charges and says the Bengal Swasthya Sathi scheme is better than the Central scheme
  • iPhone exports from India surged 33% in the period April to September this year
India warns Canada on making 'absurd and baseless' claims against Home Minister Amit Shah
oppn parties
Maiden Pharma Cough Syrup Case: Did WHO Act In Haste?

By Sunil Garodia
First publised on 2022-12-16 06:50:54

About the Author

Sunil Garodia Editor-in-Chief of indiacommentary.com. Current Affairs analyst and political commentator.

A few months ago, the World Health Organization (WHO) had insinuated that India's Maiden Pharmaceuticals, the Haryana-based drug manufacturer, had supplied sub-standard paediatric cough syrups to Gambia and linked it to the death of 66 children in that country. Now, after the results of the tests conducted on the samples of final products and raw materials drawn from the manufacturing facilities of the drug firm have confirmed that there was nothing wrong with the syrups and they met with all prescribed standards, the government of India has slammed the WHO for drawing hasty conclusions and unfairly linking the death of the children to the alleged infirmities in the cough syrups without conducting a thorough test. Surprisingly, as the government has stated, WHO has, till now, refused to share any details as to how it arrived at the conclusion that linked the deaths to the cough syrups despite several reminders.

The hasty action of WHO is not acceptable, more so as it has failed to produce material to support the claims. India has earned the reputation of supplying excellent quality pharmaceuticals products all over the world. Its companies follow good manufacturing practices and are being regularly inspected by local authorities and even international authorities. If baseless charges, not backed by supporting material, are made against one Indian company it will damage the reputation of the entire industry.

India must take up the matter with WHO at the highest level. It should submit the findings of the tests conducted and demand the same from WHO. If WHO is unable to substantiate its claims then it should issue an unconditional apology and clear the drug manufacturer. Further, there must a defined process at WHO through which such alerts are issued. It must do so only after conducting acceptable preliminary tests and provide the results to the government of the originating country. In case of Maiden Pharmaceuticals it seems that WHO is trying to hide its inefficiency as it has failed to provide supporting material even though nearly three months have passed since it first sounded the alert. This is damaging for the whole pharmaceuticals ecosystem.